 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
2 News |  |
- MK-2578 (darbepoetin alfa biosimilar) / Merck (MSD)
Enrollment change: A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12) (clinicaltrials.gov) - Feb 27, 2012
P2, N=39, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=158 --> 39
- MK-2578 (darbepoetin alfa biosimilar) / Merck (MSD)
Enrollment change: A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002) (clinicaltrials.gov) - Nov 9, 2011
P2b, N=7, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=158 --> 39 N=75 --> 7